LITTLETON, Colo. — November 19, 2025 — Leads & Copy — Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its third quarter 2025 financial results after the market closes today, November 19, 2025. A conference call will follow at 5:00 p.m. Eastern time to review the results and provide operational updates.
Investors and interested parties can access the conference call by dialing (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call by dialing (844) 512-2921, or (412) 317-6671 for international callers, using the passcode 1186460. The replay will be available until December 3, 2025.
A live webcast of the conference call can be accessed on Vivos’ website, with an online archive available for 30 days following the call.
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company, focuses on developing and commercializing diagnostic and treatment methods for breathing and sleep issues related to dentofacial abnormalities, such as obstructive sleep apnea (OSA) and snoring in adults. The company’s devices are cleared by the FDA for adult patients with all severity levels of OSA and for children ages 6 to 17 with moderate-to-severe OSA.
Vivos’ Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, with 90% remaining undiagnosed. The disorder is linked to many serious chronic health conditions. Vivos aims to change this through technology, education, and collaborations with sleep healthcare providers.
The Vivos Method, using the company’s appliances and protocols, offers a non-surgical, non-invasive, and non-pharmaceutical solution for treating OSA.
Vivos encourages investors and other interested parties to join its conference call today to hear more about the company’s strategic collaborations and their anticipated effect on near-term revenue growth and cash burn.
Bradford Amman, Chief Financial Officer and Investor Relations Contact, can be reached at investors@vivoslife.com.
Source: Vivos Therapeutics, Inc.
Source: Vivos Therapeutics, Inc.
